Compare BIOX & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIOX | OTLK |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 29.2M |
| IPO Year | 2019 | 2016 |
| Metric | BIOX | OTLK |
|---|---|---|
| Price | $0.47 | $0.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $4.33 | $2.50 |
| AVG Volume (30 Days) | 308.0K | ★ 4.4M |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | $37.82 | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.16 |
| 52 Week High | $5.18 | $3.39 |
| Indicator | BIOX | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 43.97 |
| Support Level | $0.42 | $0.17 |
| Resistance Level | $0.68 | $0.29 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 8.75 | 27.43 |
Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.